Cohance Lifesciences Invests USD 10 Million in cGMP Bioconjugation Suite

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Cohance Lifesciences (BSE: 543064, NSE: COHANCE) is investing USD 10 million to expand its cGMP bioconjugation capabilities at its U.S.-based subsidiary, NJ Bio, the company announced.

The investment is geared toward supporting innovators from early development through late-phase clinical supply, enhancing NJ Bio's cGMP bioconjugation capabilities to supply full Antibody-Drug Conjugates (ADCs) up to Phase 2b clinical studies.

The expansion aims to strengthen the integrated offering in ADCs, combining payload-linker synthesis and bioconjugation.

NJ Bio is currently executing a major program for an existing innovator customer with multiple ADC candidates, supporting Phase 1 and Phase 2 clinical studies.

The new suite will have the flexibility to manufacture up to 2 kg of ADCs, designed to handle high-potent drug substances, for clinical requirements. The facility is expected to be operational by the end of Q4FY26, with bioconjugation work commencing thereafter.

Vivek Sharma, Executive Chairman of Cohance Lifesciences, noted the investment as a pivotal milestone in the ADC space.

Cohance Lifesciences, formerly Suven Pharmaceuticals, reported revenue of INR 26 billion (~USD 313 million) with 33.6% adjusted EBITDA margins in FY25.

NJ Bio is in discussions with three to four additional customers whose ADC programs are expected to transition to cGMP manufacturing upon commissioning of the expanded suite. NJ Bio has expanded its linker-payload capabilities with a dedicated lab, completing one GMP campaign with two more underway.

The global ADC market is experiencing growth due to rising cancer incidence. NJ Bio's single-site CRDMO model aligns with the preference for seamless, end-to-end execution.

For investor relations, contact Cyndrella Carvalho, Head - Investor Relations, Cohance Lifesciences Limited or Gavin Desa / Rishab Barar, CDR India.

In FY25, Cohance Lifesciences reported revenue of INR 26 billion (~USD 313 million) with 33.6% adjusted EBITDA margins.